Genmab A (GMAB) Net Income - Minority (2018 - 2026)
Genmab A's (GMAB) quarterly Net Income - Minority came in at -$3.0 million in Q1 2026, up 13.26% YoY from -$2.7 million in Q1 2025, and up 10.15% on a QoQ basis from -$3.4 million in Q3 2025.
Genmab A (GMAB) Net Income - Minority (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Net Income - Minority data on file, last reported at -$3.0 million in Q1 2026.
- Quarterly Net Income - Minority rose 13.26% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.0 million (up 13.26% YoY) and the FY2025 annual result came in at -$3.5 million, up 21.49% from the prior year.
- Net Income - Minority grew to -$3.0 million in Q1 2026, from -$3.4 million in the prior quarter.
- In the past five years, Net Income - Minority ranged from a high of -$2.9 million in Q4 2024 to a low of -$4.4 million in Q1 2024.
- A 3-year average of -$3.4 million and a median of -$3.4 million in 2024 frame the typical range for Net Income - Minority.
- The widest YoY moves for Net Income - Minority: up 21.49% in 2025, down 0.89% in 2025.
- Tracing GMAB's Net Income - Minority over 3 years: stood at -$2.9 million in 2024, then dropped by 15.12% to -$3.4 million in 2025, then gained by 10.15% to -$3.0 million in 2026.
- The last three Net Income - Minority figures came in at -$3.0 million (Q1 2026), -$3.4 million (Q3 2025), and -$3.5 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.01 Mn |
| Sep 30, 2025 | -3.35 Mn |
| Mar 31, 2025 | -3.47 Mn |
| Dec 31, 2024 | -2.91 Mn |
| Sep 30, 2024 | -3.38 Mn |
| Mar 31, 2024 | -4.42 Mn |
| Sep 30, 2020 | -8.09 |
| Dec 31, 2019 | -7.22 |
| Sep 30, 2019 | -7.22 |
| Dec 31, 2018 | -8,770.00 |